
|Articles|May 20, 2020
ASCRS 2020: Intraocular dexamethasone, moxifloxacin vs topical regimen
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' David Hutton speaks with John A. Hovanesian, MD, about the highlights of his presentation on patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin versus a topical regimen, during the 2020 ASCRS virtual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease
3
Breaking down the barriers: Ophthalmic care in the incarcerated population
4
AAO 2025: Diana Do reviews the real-world use of aflibercept 8 mg
5